Recently, thiazolidinone derivatives have been widely studied as antiparasitic agents. Previous investigations showed that fused 4-thiazolidinone derivatives (especially thiopyranothiazoles) retain pharmacological activity of their synthetic precursors-simple 5-ene-4-thiazolidinones. A series of isothiochromeno[4a,4-d][1,3] thiazoles was investigated in an in vitro assay towards bloodstream forms of Trypanosoma brucei brucei. All compounds inhibited parasite growth at concentrations in the micromolar range. The established low acute toxicity of this class of compounds along with a good trypanocidal profile indicates that isothiochromenothiazole derivatives may be promising for designing new antitrypanosomal drugs.
Introduction
African Trypanosomiasis or sleeping sickness is one of the so-called world's neglected diseases affecting population in sub-Saharan Africa. It is caused by the parasites Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense and transmitted by the tsetse fly. Despite the fact that the number of cases reported in recent years has significantly decreased [1] , nearly 60 million people remain at risk of infection. No new drugs for the African trypanosomiasis treatment have been approved since the early 1990s. The latter along with the absence of a vaccine or drugs for prophylaxis, the toxicity and the insufficient efficiency activity of the existing drugs, attest to the development of new efficient and safe antitrypanosomal agents. American trypanosomiasis or Chagas disease is caused by Trypanosoma cruzi transmitted by the triatomine bug. About 7 million people are infected by this parasite, mainly in Latin America. Due to human migration, the potential spreading of Chagas disease to other continents is alarming (e.g., transmission by blood transfusion). Our therapeutic arsenal against Chagas disease is furthermore very limited, with toxic drugs. So, the need for new chemotherapeutics for the American trypanosomiasis treatment is topical [2] . Moreover, it is worth mentioning that the discovery of highly active antitrypanosomals is of special interest for the search for drugs against other parasitic diseases, such as Leishmaniasis or Malaria [3, 4] . This is argued by some phylogenetical similarities between protozoan parasite targets, such as dihydropholate reductase [5] or topoisomerase I [6] . heated under reflux for 4-5 h and precipitated with water. Resulting precipitate was filtered off and recrystallized from acetonitrile (2, 5, 10, 11), ethanol:water mixture (1:1) (3, 4, 12, 13), toluene:hexane mixture (2:1) (9), isopropanol (6, 8) , acetic acid:water mixture (1:1) (7). 
Pharmacology

Antitrypanosomal Activity Assay
Bloodstream forms of Trypanosoma brucei strain 90-13 were cultured in HMI9 medium supplemented with 10% FCS (fetal calf serum) at 37 • C under an atmosphere of 5% CO 2 [34] . In all experiments, log-phase parasite cultures were harvested by centrifugation at 3000× g and immediately used. Drug assays were based on the conversion of a redox-sensitive dye (resazurin) to a fluorescent product by viable cells as previously described [35, 36] . Drug stock solutions were prepared in pure DMSO. Trypanosoma brucei bloodstream forms (10 3 cells/well) were cultured in 96-well plates either in the absence or in the presence of different concentrations of inhibitors in a final volume of 200 µL. After 72 h incubation, resazurin solution was added in each well at the final concentration of 45 µM and fluorescence was measured at 530 nm and 590 nm absorbance after a further 4 h incubation. The percentage of inhibition of parasite growth rate was calculated by comparing the fluorescence of parasites maintained in the presence of drug to that of in the absence of drug. DMSO was used as control. Concentration inhibiting 50% of parasite growth (IC 50 ) was determined from the dose-response curve with drug concentrations ranging from 10 to 0.625 µg/mL and presented in µM.
Sci
Acute Toxicity In Vivo
The experiments were conducted on white male mice weighing 23-25 g. Compounds were dissolved in saline solution (0.9% NaCl) with 1-2 drops of Polysorbate 80 (Tween-80 ® ). After dissolution, they were administered to mice via intraperitoneal route. The LD 50 was evaluated for 4 or 5 different doses each on 6 animals and calculated by the Litchfield and Wilcoxon method [37] .
Results and Discussion
Chemistry
Isothiochromeno[4a,4-d][1,3]thiazoles 1-13 were synthesized (compounds 2, 4, 5, 9, 11, 13-resynthesized) according to the known synthetic protocol [27, 38] . Starting (5aR,8R,9aR)-5,5,8-trimethyl-3,5,5a,6,7,8,9,9a-octahydro-2H-isothiochromeno[4a,4-d] [1, 3] thiazole-2-one 1 was obtained in the Knoevenagel-hetero-Diels-Alder reaction of 3,7-dimethyloct-6-enal (citronellal) and 4-thioxo-2-thiazolidinone (isorhodanine) in the presence of ethylenediamine diacetate in acetonitrile medium at room temperature [33] . Target compounds 2-13 were synthesized in the alkylation reactions of 1 potassium salt by different chloroacetamides in ethanol. The reaction goes in situ through the stage of potassium salt formation which was not isolated (Scheme 1).
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Chemistry
Isothiochromeno[4a,4-d][1,3]thiazoles 1-13 were synthesized (compounds 2, 4, 5, 9, 11, 13-resynthesized) according to the known synthetic protocol [27, 38] . Starting (5aR,8R,9aR)-5,5,8-trimethyl-3,5,5a,6,7,8,9,9a-octahydro-2H-isothiochromeno[4a,4-d] [1, 3] thiazole-2-one 1 was obtained in the Knoevenagel-hetero-Diels-Alder reaction of 3,7-dimethyloct-6-enal (citronellal) and 4-thioxo-2-thiazolidinone (isorhodanine) in the presence of ethylenediamine diacetate in acetonitrile medium at room temperature [33] . Target compounds 2-13 were synthesized in the alkylation reactions of 1 potassium salt by different chloroacetamides in ethanol. The reaction goes in situ through the stage of potassium salt formation which was not isolated (Scheme 1). Structure and purity of compounds were confirmed by NMR spectroscopy and chromatography data (experimental part). Stereoconfiguration of compounds were assigned based on our previous data (spectral data, X-ray analysis) [33] . (Table 1) comparable to Nifutimox (IC50 = 2.39 µM). Increasing activity from the starting compound 1 (IC50 = 29.3 µM) as well as 2 (IC50 = 44.4 µM) proves the necessity of aryl substituents in the N3 position of the main core for the trypanocidal activity. Substituents in the aryl fragment also influence the antitrypanosomal activity. For example, halogen atoms in the aryl moiety significantly increase the inhibition activity of derivatives 10-13 (IC50 ranging from 2.97 to 8.50 µM). Interestingly, previously tested and structurally related thiopyranothiazoles with a norbornane moiety and the same fragments in the N3 position of the thiazolidine core [29] showed the same levels of IC50 values against Trypanosoma brucei. Probably, an acetamide moiety with different substituents in the aryl ring has an impact on the spatial arrangement of atoms that increases the molecules affinity to the yet unknown biotarget. On the other hand, an ester moiety in the aryl ring of 9 also highly contributes to the trypanocidal activity (IC50 = 1.55 µM).
Pharmacology
Establishment of any anticancer and antitrypanosomal activity correlation for isothiochromenothiazoles was also an issue of the study. Previously, some of the synthesized isothichromenothiazoles were studied for their anticancer activity within a Developmental Therapeutic Program protocol (National Cancer Institute, Bethesda, MD, USA) [27] . Among Structure and purity of compounds were confirmed by NMR spectroscopy and chromatography data (experimental part). Stereoconfiguration of compounds were assigned based on our previous data (spectral data, X-ray analysis) [33] . (Table 1) comparable to Nifutimox (IC 50 = 2.39 µM). Increasing activity from the starting compound 1 (IC 50 = 29.3 µM) as well as 2 (IC 50 = 44.4 µM) proves the necessity of aryl substituents in the N3 position of the main core for the trypanocidal activity. Substituents in the aryl fragment also influence the antitrypanosomal activity. For example, halogen atoms in the aryl moiety significantly increase the inhibition activity of derivatives 10-13 (IC 50 ranging from 2.97 to 8.50 µM). Interestingly, previously tested and structurally related thiopyranothiazoles with a norbornane moiety and the same fragments in the N3 position of the thiazolidine core [29] showed the same levels of IC 50 values against Trypanosoma brucei. Probably, an acetamide moiety with different substituents in the aryl ring has an impact on the spatial arrangement of atoms that increases the molecules affinity to the yet unknown biotarget. On the other hand, an ester moiety in the aryl ring of 9 also highly contributes to the trypanocidal activity (IC 50 = 1.55 µM). N-{5,5,8-trimethyl-3,5,5a,6,7,8,9,9a-oktahydro-2H-isothiochromeno[4a,4-d]thiazol-2-on-3-yl}-acetamide 2. For derivatives with the highest trypanocidal activity, 9, 10, and 13 and the starting compound 1, the acute toxicity (mice) was studied and their LD50 were determined [35, 36] . The stock solutions of the compounds used in this study were prepared immediately before usage and increasing amounts of substances (100-1000 mg/kg) were injected intraperitoneally. The LD50 values were calculated according to Litchfield and Wilcoxon. These derivatives show a little acute toxicity in mice with LD50 values within the range of 240-480 mg/kg. Establishment of any anticancer and antitrypanosomal activity correlation for isothiochromenothiazoles was also an issue of the study. Previously, some of the synthesized isothichromenothiazoles were studied for their anticancer activity within a Developmental Therapeutic Program protocol (National Cancer Institute, Bethesda, MD, USA) [27] . Among isothiochromeno[4a, 4-d] -on-3-yl}-acetamide 5 was tested in a range of concentrations from 0.1 to 100 µM and showed the highest growth inhibitory levels (GI 50 ) against cell lines of leukemia, non-small-cell lung cancer and prostate cancer [27] . One more argument in favor of a dual action for the tested derivatives is a significant decrease of trypanocidal potential and the absence of anticancer activity (inhibition of cancer cells growth less than by 20%) for N-{5,5,8-trimethyl-3,5,5a,6,7,8,9 ,9a -oktahydro-2H-isothiochromeno[4a,4-d]thiazol-2-on-3-yl}-acetamide 2.
For derivatives with the highest trypanocidal activity, 9, 10, and 13 and the starting compound 1, the acute toxicity (mice) was studied and their LD 50 were determined [35, 36] . The stock solutions of the compounds used in this study were prepared immediately before usage and increasing amounts of substances (100-1000 mg/kg) were injected intraperitoneally. The LD 50 values were calculated according to Litchfield and Wilcoxon. These derivatives show a little acute toxicity in mice with LD 50 values within the range of 240-480 mg/kg.
Conclusions
A series of isothiochromeno[4a,4-d] [1, 3] thiazole derivatives was synthesized and investigated in an in vitro assay against Trypanosoma brucei brucei. Compounds showed inhibitory activity towards the parasite growth at concentrations in the micromolar range. Structure-activity relationships reveal the positive influence of N3-substituent for the trypanocidal activity. The same trend was found for the anticancer activity of compounds. This is an additional argument in favor of the search for compounds with dual action (antitrypanosomal and anticancer). Along with this, low acute toxicity of compounds indicates that isothiochromenothiazoles may be used in further directed design of antitrypanosomal agents.
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